COVID 19 with Cardiac Injury Complication, A case Report by Saus, Puti Sarah et al.
 
 
COVID 19 with Cardiac Injury Complication, A case Report 
 
Puti Sarah Saus, Dicky Hanafi, Rossana Barrack 
Metropolitan Medical Centre Hospital 
 
Abstract 
 
Background : The Corona virus Disease COVID-19 have been independently 
associated with the cause of pneumonia and acute respiratory distress syndrome 
with high risk of mortality. Mounting evidence substantiates the presence of cardiac 
injury in patients with COVID-19. Although a recent study reported that 12% of 
patients had COVID-19 associated acute cardiac injury. 
Case presentation : A 38 year old male was admitted with pneumonia and cardiac 
symptoms. He was genetically confirmed as COVID-19 by swab PCR testing, 1 
week after admission. He also had elevated CKMB and Hs troponin T level, high 
Ferritin level, CRP, lymphopenia, and a slight increase in N/L ratio. Chest 
radiography showed bilateral pneumonia. The patient was confirmed to the diagnosis 
of Myocardial injury. After receiving tocilizumab and immunoglobulin, his condition 
improved gradually with the declining laboratory inflammation marker, but there was 
a secondary infection with an increased of leucocyte and worsen chest radiography, 
escalating antibiotic and metilprednisolon was given, the patient gradually improving.  
Conclusion : COVID-19 patients may develop cardiac complication such as cardiac 
injury or myocarditis, and this is our first case of COVID-19 infection complicated 
with cardiac injury.  
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 Background 
The first case of coronavirus disease 2019 (COVID-19) were reported on the 31 
december 2019 in Wuhan City, Hubei Province of China. 1 Later on, a series of  
pneumonia cases have been reported in Jakarta, Indonesia since march 2020. The 
outbreak of a new coronavirus have clinical manifestations very similar to viral 
pneumonia. Common symptoms are fever, cough, myalgia and/or fatigue, even 
diarhhea. All patients had pneumonia and chest radiography showed abnormalities.2 
Complications include acute respiratory distress syndrome (ARDS), acute cardiac 
injury, and secondary infections. Here, we describe a case of COVID-19 infection 
complicated with myocardial Injury. 
 
Case report 
A 38 years old male was admitted to the hospital with symptoms of fever, cough, 
shortness of breath and chest tightness 3 days before admission. Two weeks prior to 
admission he was diagnosed with hypertension and was treated with telmisartan. He 
had no History of previous contact with covid positif patient or history of travelling 
abroad. On arrival to the emergency department, physical examination revealed 
blood pressure of 130/90 mmHg, heart rate of 90x/mnt, oxygen saturation of 98% 
with nasal oxygen and body temperature of 38 0C. From cardiac auscultation, Heart 
sounds (S1 & S2) regular, no murmur, nor gallop. Lungs were within normal limits. 
No pitting edema on both extremities. A 12 lead electrocardiogram showed diffuse 
inverted T waves in almost all leads ( II,III, aVF, V2-V6 ). (Figure 1A). Findings on 
the chest radiography was bilateral pneumonia in base of the lungs. (Figure 1B). 
Blood test showed elevated levels markers of myocyte necrosis (high-sensitivity 
troponin T level of 25.47 pg/mL and creatine kinase–MB level of 35.9 U/L). A normal 
N-Terminal brain natriuretic peptide (NT-ProBNP level ) 41 Ng/L level. An increase of 
White cell counts, with low Lymphocyte ( 18 % ) and a slight increase in netrofil 
lymphocyte ratio (3.78). Blood sample test also revealed increase in ALT, AST, 
Ferritin, LDH ( lactate dehydrogenase, low in albumin, and a slight increase in C-
reactive protein (CRP) and normal PCT ( Procalcitonin). ( Table 1). 
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 The patient was admitted in our isolation ward with a diagnosis of suspected 
myocarditis and pneumonia. A Nasopharyngeal swab was performed with a positif 
result for SARS-CoV-2 on real-time reverse transcriptase-polymerase chain reaction 
assay. Unforfunately we cannot conduct an echocardiography due to lack of mobile 
echocardiography. and also based on a normal cardiac size from the chest 
radiogram and a normal Nt-Pro BNP we assumed the patient was not in heart failure. 
On the two days of his hospitalization, the patient clinically deteriorated, his oxygen 
saturation was 89 % on NRM 15 Lpm, but his blood pressure and heart beat was 
relatively stable ( 120-70 mmHg and 90-95 x/mnt).  We decided to treat him with 
Tocilizumab 4mg/kg iv drip, Immunoglobulin 400mg/kg/day for 10 days, and 
hydroxychloroquine 200mg twice daily. We also give him supportive medication and 
antibiotics. Chest radiography was repeated on day 6 worsen with infiltrate and 
opacities in middle part of both lungs and his clinical state were relatively 
unchanged. We again planned to give him tocilizumab with a higher dosis ( 8mg/kg 
iv drip) but unfortunately the medicine was no longer available because they stop 
producing. We decided to give oseltamivir, hence the medicine only can be given by 
the government if the nasopharyngeal swab is positive. So we gave him oseltamivir 
twice daily 75mg for 10 days. On the 14th day of hospitalization blood test marker 
elevated ( leucocyte 16.40  10^3 /L ) so we  escalated the antibiotic from 
meropenem to piperacillin & tazobactam for 10 days and gave metilprednisolon and 
heparin drip, the patient clinically and laboratory improving, eventhough chest x ray 
stated otherwise. We conducted CT thoracal and revealed ground glass appearance 
and fibrosis in both lungs. He was discharge on day 30 of hospitalization with good 
clinical condition. (Figure 2. ) 
 
Discussion 
We describe a patient with a history of hypertension admitted to the hospital with 
COVID-19 and myocardial injury. Our findings develop severe pneumonia with 
cardiac  symptoms, as the following features: chest pain, shortness of breath, dry 
cough, fever and diarrhea. While the spectrum of clinical manifestation is highly 
related to the inflammation process of the respiratory tract, this case provides 
evidence of cardiac involvement as a possible phenomenon of the viral respiratory 
infection.  Previous coronavirus outbreaks have been associated with a significant 
burden of cardiovascular comorbidities and complications.3
 
Furthermore, the severity 
of the primary respiratory syndrome and risk of adverse outcomes is increased in 
patients with pre-existing cardiovascular diseases. Hypotension, tachycardia, 
bradycardia, arrhythmia, or even sudden cardiac death are common in patients with 
SARS. Electrocardiographic changes and troponin elevation may signal underlying 
myocarditis. 4  The cardiovascular system is often involved in COVID-19 early, 
reflected in the release of highly sensitive troponin and natriuretic peptides, which 
are all extremely prognostic, particularly in those showing continued rise, along with 
cytokines such as IL-6.5 Inflammation in the myocardium can result in myocarditis, 
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heart failure, cardiac arrhythmias, acute coronary syndrome, rapid deterioration and 
sudden death.  
The beta-coronavirus virus underlying COVID-19 strains from the same species as 
SARS and has recently been named SARS-CoV-2. SARS-CoV binds to cells 
expressing appropriate viral receptors, particularly angiotensin-converting enzyme 2 
(ACE2).  Angiotensin converting enzyme 2 is also expressed in the heart, providing a 
link between coronaviruses and the cardiovascular system. SARS-CoV can down-
regulate myocardial and pulmonary ACE2 pathways, thereby mediating myocardial 
inflammation, lung oedema, and acute respiratory failure. 5  As in this case, 
hypertension was a predisposing factor causing a relatively young patient into a 
severe pneumonia and myocarditis, shown in the Increase of cardiac troponin levels 
as a sensitive marker of myocardial injury.   
A rapid progression of the pneumonia could possibly due to virus overload called 
cytokines storm.  Cytokine storm refers to the phenomenon of rapid and massive 
production of various cytokines in body fluid after the organism is infected with 
microorganisms, which is an important cause of acute respiratory distress syndrome 
and multiple organ failure. Cardinal features of unremitting fever, cytopenias 
hyperferritinemias, and pulmonary involvement is a hyperinflammatory syndrome in 
other word cytokine syndrome.6 A study showed that after SARS-CoV infection, 
interferon-related cytokine storms may be involved in the immunopathology of SARS 
patients .7 IL-6 is a cytokine that plays an important role in inflammatory reaction and 
immune response. 8 The patient had significantly elevated interleukin, shown from the 
high ferritin marker suggesting the presence of cytokine storms and also 
lymphopenia. Lymphopenia is a common feature in the patients with COVID-19 and 
might be a critical factor associated with disease severity and mortality. For this 
reason tocilizumab was recommended in COVID-19 patient to prevent or treat 
cytokines storms, function as an anti-IL6 reseptor antibody. 9 As seen in  our  patient, 
tocilizumab helped stabilize the patient condition by preventing the disease 
acceleration into ARDS ( acute respiratory distress syndrome). 
In parallel, we also give intravenous immunoglobulin, IVIg (intravenous 
immunoglobulin ) is a blood product containing polyclonal immunoglobulin G isolated 
and pooled from healthy donors.  As a complex preparation, it contains a large 
number of bioactive moieties, and the entirety of its effects is not yet fully 
understood. IVIg of higher dose has been a choice of immunomodulatory therapy for 
autoimmune or inflammatory disease and for prophylaxis and treatment of severe 
infections, especially in immunocompromised patients. 10 Considering its efficacy in 
improving passive immunity and modulating immune inflammation and the overall 
safety profile, high-dose IVIg could be considered a promising option at the early 
stage of clinical deterioration of patients with COVID-19.   Therefore delaying the 
acceleration of the disease, immunoglobulin was given for 10 days and proven to 
supress the inflammation.  
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 Limitations  
 An echocardiography was not performed due to the unavailability of mobile 
echocardiograpy in our centre giving a limitations in reporting the valvular & 
myocardial damage that may cause from the myocarditis or myocardial injury.  
 
 
Conclusions  
Cardiac injury may develop among patients hospitalized with COVID-19, and it is 
associated with a higher risk of in-hospital mortality. Although the exact mechanism 
of cardiac injury needs to be further explored, the findings presented in this case 
highlight the proper and early diagnostic, also prompt treatment in the early phase of 
the disease can prevent further damage, although definite therapy is not yet 
conclusive. Further study is needed to overcome and minimize cardiac complication 
of COVID-19. 
 
Figure 1. Electrocardiographic and Chest Radiographic Findings             
A Electrocardiography                                                                       B. Chest Radiography 
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A. Electrocardiography showing sinus rhythm with diffuse T-wave inversion in leads V2-V6 and II,III,avF & 
I,aVL. 
B. Posteroanterior chest radiography at presentation showed bilateral pneumonia. 
 
Table 1. Clinical Laboratory Results  
Measure Reference range Result   
  Day 1 Day 13 Day 29 
Red blood cell 
count  
4.50- 5.50   10^6/L 4.84 4.77 4.22 
Hemoglobin  13.0- 16.0      g/dL 15.4 14.4 13.0 
Hematocrit  40.0- 48.0    % 42.7 40.7 37.6 
White blood cell 
count  
5.00- 10.00    10^3/ L 5.99 16.42 12.91 
Lymphocyte count  20-40    % 20  15 
Platelet count,  150- 400    10^3/ L 191  292 
Neutrofil limfosit 
ratio 
< 3.13 3.78  4.87 
Sodium  135.0 – 147.0  mmol/L 136.7   
Potassium 3.50 – 5.00   mmol/L 3.15   
Chloride  94.0 – 111.0  mmol/L 98.8   
Ureum 10- 50   mg/dL 17 18  
Creatinine  <1.40   m/dL 0.73 0.48  
C-reactive protein  < 5.00   mg/L 36.13  4.60 
Creatine kinase– U/L 45   
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MB  
High-sensitivity 
troponin T 
Pg/mL 23.78  16.28 
NT-proBNP  < 125  ng/L 41   
Albumin 3.50 – 5.20   g/dL 2.79   
ALT 10- 34   U/L 153 65  
AST 9 - 43  U/L 138 56  
D- Dimer < 500   Ng/mL 1640 1120 420 
Procalcitonin <= 0.5   Ng/mL 0.325 0.055  
Ferritin 30-400  Ng/mL 1894 1894 457.10 
LDH 240-480  U/L 827 827  
 
Figure 2.  
 
Figure 2. computerized tomography on the 15th day showed typical ground-glass changes of viral 
pneumonia and fibrosis.  
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